veterinary autoimmune disease therapeutics market, veterinary autoimmune disease therapeutics market size, veterinary autoimmune disease therapeutics market share, veterinary autoimmune disease therapeutics market outlook, veterinary autoimmune disease therapeutics market data, veterinary autoimmune disease therapeutics market report
At what pace is the veterinary autoimmune disease therapeutics market growing, and what is its estimated value?
The veterinary autoimmune disease therapeutics market size has grown strongly in recent years. It will grow from $3.25 billion in 2024 to $3.47 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to advances in immunology, increased pet ownership, improved diagnostic methods, development of new drug classes, and rising awareness of pet health.
The veterinary autoimmune disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in biotechnology, growing investment in veterinary healthcare, increasing prevalence of autoimmune diseases in pets, development of novel therapeutics, and rising pet insurance adoption. Major trends in the forecast period include personalized medicine, the use of biologics, the integration of telemedicine, adoption of regenerative therapies, and focus on holistic and integrative treatments personalized medicine, use of biologics, integration of telemedicine, adoption of regenerative therapies, and focus on holistic and integrative treatments.
Get Your Free Sample of The Global Veterinary Autoimmune Disease Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16208&type=smp
What are the top drivers to the rising demand in the veterinary autoimmune disease therapeutics market?
The increasing funding for research in veterinary medicine is expected to propel the growth of the veterinary autoimmune disease therapeutics market going forward. Veterinary medicine is the branch of medicine that deals with the prevention, diagnosis, and treatment of diseases, disorders, and injuries in animals. The increased funding for research in veterinary medicine can be attributed to rising zoonotic diseases, the growing pet industry, advances in animal health technology, agricultural demands, and wildlife conservation efforts. Funding for research in veterinary autoimmune disease supports studies on disease mechanisms, diagnostic tools, and treatment options, enhancing veterinary medicine’s ability to diagnose and manage these conditions effectively. For instance, in August 2024, according to the National Institute of Food and Agriculture, a US-based department of agriculture announced 20 the Veterinary Service Grants Program (VSGP) with NIFA for investing $3.2 million in rural food animal veterinary medicine in the fiscal year 2022, across the United States. Therefore, the increased funding for research in veterinary medicine is driving the growth of the veterinary autoimmune disease therapeutics market.
How is the veterinary autoimmune disease therapeutics market segmented?
The veterinary autoimmune disease therapeutics market covered in this report is segmented –
1) By Therapy Type: Corticosteroids, Azathioprine, Cyclosporine, Mycophenolate, Leflunomide, Cyclophosphamide, Levothyroxine, Folic Acid, Hydroxychloroquine, Chloroquine
2) By Animal Type: Companion Animals, Livestock Animals, Other Animals
3) By Disease: Hypothyroidism, Pemphigus Disease, Canine Lupus, Auto-Immune Hemolytic Anemia, Bullous Pemphigoid, Discoid Lupus Erythematosus (DLE), Immune-Related Arthritis, Other Diseases
4) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics
Subsegments:
1) By Corticosteroids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Triamcinolone
2) By Azathioprine: Azathioprine Oral Tablets, Azathioprine Injectable Formulation
3) By Cyclosporine: Oral Cyclosporine (Atopica), Injectable Cyclosporine
4) By Mycophenolate: Mycophenolate Mofetil (Oral Form), Mycophenolate Sodium (Injectable Form)
5) By Leflunomide: Leflunomide Tablets (Oral), Leflunomide Injection
6) By Cyclophosphamide: Oral Cyclophosphamide, Injectable Cyclophosphamide
7) By Levothyroxine: Levothyroxine Sodium Tablets (Oral), Levothyroxine Sodium Injection
8) By Folic Acid: Folic Acid Supplements (Oral), Injectable Folic Acid
9) By Hydroxychloroquine: Hydroxychloroquine Tablets (Oral), Hydroxychloroquine Injectable Formulation
10) By Chloroquine: Chloroquine Tablets (Oral), Chloroquine Injectable Formulation
Order your report now for swift delivery
Who are the top competitors in the veterinary autoimmune disease therapeutics market?
Major companies operating in the veterinary autoimmune disease therapeutics market are Pfizer Inc, Merck & Co Inc, AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company, Amgen Inc., Teva Pharmaceuticals Industries Ltd., Zoetis Inc, Boehringer Ingelheim International GmbH, Sumitomo Pharma Co. Ltd., IDEXX Laboratories Inc., Cipla Inc., Mallinckrodt Pharmaceuticals, Virbac S.A, Dechra Pharmaceuticals plc, Neogen Corporation, Vetoquinol S.A., Norbrook Laboratories Limited, Heska Corporation, Bimeda Holdings PLC, Bayer Animal Health Inc, Aratana Therapeutics Inc, Hester Biosciences Limited
What significant trends should we anticipate in the veterinary autoimmune disease therapeutics market over the forecast period?
Major companies operating in the veterinary autoimmune disease therapeutics market are focusing on developing technologically advanced solutions. Such as RenBiologics to address several critical industry demands. RenBiologics develops innovative therapies for kidney-related conditions and chronic diseases, focusing on biologics and regenerative medicine to improve outcomes in areas like renal function and transplant success. For instance, in January 2024, according to the Biocytogen, a China-based biotechnology company, launched a new sub-brand, RenBiologics, to focus on the out-licensing of fully human antibodies for therapeutic development. This initiative aims to leverage Biocytogen’s extensive library of over 400,000 fully human antibody sequences, generated through its proprietary RenMice platforms. RenBiologics will facilitate partnerships with pharmaceutical and biotechnology companies for the co-development and licensing of these antibodies, enhancing the potential for novel antibody-based therapeutics. The launch reflects Biocytogen’s commitment to becoming a global resource in antibody discovery, with a vision to expedite the development of innovative treatments across various therapeutic areas.
Which regional trends are influencing the veterinary autoimmune disease therapeutics market, and which area dominates the industry?
North America was the largest region in the veterinary autoimmune disease therapeutics market in 2023. The regions covered in the veterinary autoimmune disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Veterinary Autoimmune Disease Therapeutics Market Report 2025 Offer?
The veterinary autoimmune disease therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Veterinary autoimmune disease therapeutics refer to treatments designed to manage and alleviate animal autoimmune diseases. These therapeutics aim to modulate or suppress the immune response to reduce inflammation, prevent further tissue damage, and improve the affected animal’s overall health and quality of life. Veterinary autoimmune disease therapeutics are critical for managing these complex conditions and require a tailored approach based on the specific disease, the severity of the condition, and the individual animal’s needs.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16208
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
